Image

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

Recruiting
18 - 55 years of age
Both
Phase 1

Powered by AI

Overview

This is an open-label, randomized study to investigate subcutaneous (SC) bepirovirsen when delivered via SC injection from vial or Prefilled syringe fitted with a Safety syringe device (PFS SSD) in healthy adult participants. The aim of this study is to provide relative bioavailability data to support the transition from the vial presentation of bepirovirsen, to a ready-to-use liquid in a PFS SSD when both are given by a health care professional. The study will also assess self-administration using the PFS SDD, and the safety and tolerability of bepirovirsen.

Eligibility

Inclusion Criteria:

  • Healthy participants as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiogram (ECGs) and vital signs.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and protocol.

Exclusion Criteria:

  • Past or current medical conditions which, in the judgement of the investigator and Medical Monitor, could jeopardize the integrity of the data derived from that participant or the safety of the participant.
  • Abnormal blood pressure as determined by the investigator.
  • Positive Hepatitis B virus (HBV), Hepatitis C virus (HCV) or human immunodeficiency virus (HIV) test results.
  • Participants with signs or symptoms suggestive of Coronavirus disease 2019 (COVID-19) within 14 days of inpatient admission, or with a positive test for active COVID-19 infection before study start.
  • Past, current or intended use of over the counter or prescription medication [including herbal medications]
  • Current or prior use of creatine-containing supplements and intended use up to 50 days post-dosing.
        Prior use of immunosuppressive drugs within 3 months before dosing or interferon within 12
        months before dosing.
          -  Prior treatment with any oligonucleotide or small interfering ribonucleoside (RNA)
             siRNA within 12 months before dosing.
          -  Loss of blood or blood products in excess of 500 millilitre (mL) within any 3-month
             period during the study.
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.
          -  Current enrolment or past participation in another investigational study in which an
             investigational intervention (e.g., drug, vaccine, invasive device) was administered
             within 5-half-lives (if known) or twice the duration of biological effect (if known),
             whichever is longer, or within the last 90 days (if half-life and duration of
             biological effect are unknown), before the first dosing day in the current study.
          -  Current enrolment or past participation in this clinical study.
          -  Cotinine levels indicative of smoking or history or regular use of tobacco- or
             nicotine-containing products within 6 months prior to screening.
          -  Regular alcohol consumption of alcohol within 6 months prior to the study.
          -  Regular use of known drugs of abuse, including Tetrahydrocannabinol (THC).
          -  History of sensitivity to bepirovirsen or components thereof or a history of drug or
             other allergy that, in the opinion of the investigator or Medical Monitor
             contraindicates their participation.

Study details

Hepatitis B

NCT06058390

GlaxoSmithKline

12 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.